Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01246960 · ClinicalTrials.gov registry record · Phase 2
A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 168
- Enrollment target
NCT01246960 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 168 participants.
The verdict
NCT01246960, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 168 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether ramucirumab when used in conjunction with chemotherapy treatment can help participants with stomach, esophagus, and gastroesophageal cancer.
Interventions
- DRUG Placebo
- DRUG Leucovorin
- DRUG Oxaliplatin
- DRUG 5-Fluorouracil
- BIOLOGICAL Ramucirumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2011-04 |
| Est. Completion | 2014-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01246960
The ClinicalTrials.gov registry entry for NCT01246960 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01246960 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01246960 about?
NCT01246960 is a clinical study titled "A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer". The purpose of this study is to determine whether ramucirumab when used in conjunction with chemotherapy treatment can help participants with stomach, esophagus, and gastroesophageal cancer.
What is the current status of trial NCT01246960?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 168 participants. The study started on 2011-04. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01246960?
The interventions under investigation include: Placebo (DRUG), Leucovorin (DRUG), Oxaliplatin (DRUG), 5-Fluorouracil (DRUG), Ramucirumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01246960?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.